Sinco Pharmaceuticals Holdings Past Earnings Performance
Past criteria checks 2/6
Sinco Pharmaceuticals Holdings has been growing earnings at an average annual rate of 47%, while the Healthcare industry saw earnings growing at 4.8% annually. Revenues have been growing at an average rate of 18.6% per year. Sinco Pharmaceuticals Holdings's return on equity is 6.7%, and it has net margins of 1.7%.
Key information
47.0%
Earnings growth rate
46.5%
EPS growth rate
| Healthcare Industry Growth | 11.3% |
| Revenue growth rate | 18.6% |
| Return on equity | 6.7% |
| Net Margin | 1.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings
Apr 02
Sinco Pharmaceuticals Holdings Limited (HKG:6833) Might Not Be As Mispriced As It Looks
Mar 08Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?
Nov 07A Look At The Intrinsic Value Of Sinco Pharmaceuticals Holdings Limited (HKG:6833)
Jun 26Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?
May 30Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet
Oct 26Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Might Deserve Your Attention Today
Feb 04I Ran A Stock Scan For Earnings Growth And Sinco Pharmaceuticals Holdings (HKG:6833) Passed With Ease
Oct 25Little Excitement Around Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Earnings
Jun 10Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt
May 24Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Is An Interesting Stock
Apr 20We're Not So Sure You Should Rely on Sinco Pharmaceuticals Holdings' (HKG:6833) Statutory Earnings
Feb 16How Much Did Sinco Pharmaceuticals Holdings'(HKG:6833) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 11
Should You Be Excited About Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 51% Return On Equity?
Dec 07Revenue & Expenses BreakdownBeta
How Sinco Pharmaceuticals Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2,540 | 42 | 207 | 0 |
| 30 Sep 23 | 2,386 | 35 | 196 | 0 |
| 30 Jun 23 | 2,232 | 27 | 186 | 0 |
| 31 Mar 23 | 2,252 | 48 | 195 | 0 |
| 31 Dec 22 | 2,272 | 69 | 205 | 0 |
| 30 Sep 22 | 2,289 | 96 | 218 | 0 |
| 30 Jun 22 | 2,307 | 122 | 232 | 0 |
| 31 Mar 22 | 2,165 | 128 | 202 | 0 |
| 31 Dec 21 | 2,024 | 135 | 172 | 0 |
| 30 Sep 21 | 2,142 | 148 | 137 | 0 |
| 30 Jun 21 | 2,261 | 161 | 102 | 0 |
| 31 Mar 21 | 2,155 | 140 | 116 | 0 |
| 31 Dec 20 | 2,050 | 118 | 130 | 0 |
| 30 Sep 20 | 1,664 | 79 | 150 | 0 |
| 30 Jun 20 | 1,277 | 41 | 170 | 0 |
| 31 Mar 20 | 1,227 | 32 | 166 | 0 |
| 31 Dec 19 | 1,176 | 24 | 162 | 0 |
| 30 Sep 19 | 1,045 | -97 | 206 | 0 |
| 30 Jun 19 | 915 | -217 | 251 | 0 |
| 31 Mar 19 | 934 | -249 | 288 | 0 |
| 31 Dec 18 | 953 | -281 | 325 | 0 |
| 30 Sep 18 | 960 | -242 | 292 | 0 |
| 30 Jun 18 | 966 | -203 | 258 | 0 |
| 31 Mar 18 | 886 | -195 | 206 | 0 |
| 31 Dec 17 | 807 | -186 | 153 | 0 |
| 30 Sep 17 | 755 | -115 | 115 | 0 |
| 30 Jun 17 | 704 | -43 | 77 | 0 |
| 31 Mar 17 | 781 | -12 | 75 | 0 |
| 31 Dec 16 | 859 | 19 | 74 | 0 |
| 30 Sep 16 | 958 | 36 | 71 | 0 |
| 30 Jun 16 | 1,057 | 52 | 67 | 0 |
| 31 Mar 16 | 1,076 | 61 | 57 | 0 |
| 31 Dec 15 | 1,096 | 70 | 46 | 0 |
| 30 Sep 15 | 1,120 | 77 | 38 | 0 |
| 30 Jun 15 | 1,144 | 84 | 31 | 0 |
| 31 Mar 15 | 1,047 | 77 | 28 | 0 |
| 31 Dec 14 | 950 | 69 | 24 | 0 |
| 31 Dec 13 | 532 | 37 | 12 | 0 |
Quality Earnings: 6833 has high quality earnings.
Growing Profit Margin: 6833's current net profit margins (1.7%) are lower than last year (3.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6833 has become profitable over the past 5 years, growing earnings by 47% per year.
Accelerating Growth: 6833's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 6833 had negative earnings growth (-39%) over the past year, making it difficult to compare to the Healthcare industry average (13.4%).
Return on Equity
High ROE: 6833's Return on Equity (6.7%) is considered low.